The initial success of the copyright undeniably revolutionized the drug landscape, but placing funds in companies heavily reliant on unbranded versions presents a complex picture. Although early returns were substantial, the cessation of patents and the appearance of less expensive alternatives have weakened sales. Consequently, a thorough evaluati